BOEHRINGER INGELHEIM PHARMA GMBH & CO. K – Trademark Portfolio

Entity Type: 28

BOEHRINGER INGELHEIM PHARMA GMBH & CO. K holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include SPIRIVA and AGGRENOX. The owner is based in INGELHEIM.

Binger Straße 173

INGELHEIM 55218 , DE

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

SPIRIVA
SPIRIVA
Registered 1998
AGGRENOX
AGGRENOX
Registered 1997

Trademark Classifications

BOEHRINGER INGELHEIM PHARMA GMBH & CO. K's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does BOEHRINGER INGELHEIM PHARMA GMBH & CO. K have?

BOEHRINGER INGELHEIM PHARMA GMBH & CO. K has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does BOEHRINGER INGELHEIM PHARMA GMBH & CO. K file in?

BOEHRINGER INGELHEIM PHARMA GMBH & CO. K files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are BOEHRINGER INGELHEIM PHARMA GMBH & CO. K's most well-known trademarks?

BOEHRINGER INGELHEIM PHARMA GMBH & CO. K's registered trademark portfolio includes well-known marks such as SPIRIVA and AGGRENOX. These are among 2 currently registered trademarks in the portfolio.

What is BOEHRINGER INGELHEIM PHARMA GMBH & CO. K's trademark registration success rate?

BOEHRINGER INGELHEIM PHARMA GMBH & CO. K has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.